{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:36:16Z","timestamp":1792442176358,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Elevated Lipoprotein(a) Lp(a) levels are associated with coronary atherosclerosis as detected by cardiac computed tomography angiography (CCTA). However, quantitative data including coronary plaque volumes and characteristics are scarce. The current study evaluated the sex-specific correlations between (Lp(a)) levels and the extent and composition of coronary stenosis and plaques.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>1,946 patients undergoing CCTA (third-generation dual-source scanner) for suspected coronary artery disease were included whose Lp(a) levels were available. Lp(a) values\u2009\u2265\u2009125\u00a0nmol\/L were classified as high.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      High Lp(a) levels were observed in 336 patients, who had greater maximum degree of stenosis (49.5\u2009\u00b1\u200926.4% vs. 43.5\u2009\u00b1\u200927.6%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002), mainly as a result of the pronounced difference in males (53.8\u2009\u00b1\u200926.0% vs. 46.2\u2009\u00b1\u200926.8%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001). A strong correlation between higher Lp(a) values and high-risk plaque features was noted in the overall cohort (odds ratio [OR]: 1.645; 95% confidence interval [CI]: 1.011 to 2.593;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.037), independent of age and LDL-cholesterol values. In males, high Lp(a) levels were associated with greater total plaque volumes (118.1 [IQR 18.3\u2013284.4] vs. 83.2 [IQR 11.8\u2013226.3] mm\n                      <jats:sup>3<\/jats:sup>\n                      ,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.018, Pint\u2009=\u20090.09), including fibrotic components (27.6 [IQR 2.1\u2013109.9] vs. 18.2 [IQR 0.4\u201365.0] mm\n                      <jats:sup>3<\/jats:sup>\n                      ,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.011, Pint\u2009=\u20090.013), whereas in women, only a marginal linear correlation with total plaque volume was observed (19.2 vs. 8.1 mm\n                      <jats:sup>3<\/jats:sup>\n                      ; Spearman\u2019s rank correlation R\u2009=\u20090.16,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.037).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study identifies novel sex-specific correlations between Lp(a) levels and coronary plaque characteristics. High Lp(a) levels in men seems to be associated with increased fibrotic plaque volumes and may contribute to greater total plaque burden and high-risk plaque features.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-025-02770-w","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:22:20Z","timestamp":1759994540000},"page":"1739-1751","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sex-specific influence of Lipoprotein(a) levels on coronary plaque characteristics: - The COPRODUCTION Registry -"],"prefix":"10.1007","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7390-5287","authenticated-orcid":false,"given":"Philipp","family":"Breitbart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Liebetrau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Gr\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Eggebrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edelgard","family":"Lindhoff-Last","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Westermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Voigtl\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Schmermund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"2770_CR1","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","volume":"302","author":"S Erqou","year":"2009","unstructured":"Erqou S, Kaptoge S, Perry PL et al (2009) Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302:412\u2013423","journal-title":"JAMA"},{"key":"2770_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","volume":"41","author":"AP Patel","year":"2021","unstructured":"Patel AP, Wang M, Pirruccello JP et al (2021) Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease. Arterioscler Thromb Vasc Biol 41:465\u2013474","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2770_CR3","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.jacc.2024.02.031","volume":"83","author":"ND Wong","year":"2024","unstructured":"Wong ND, Fan W, Hu X et al (2024) Lipoprotein(a) and long-term cardiovascular risk in a multi-ethnic pooled prospective cohort. J Am Coll Cardiol 83:1511\u20131525","journal-title":"J Am Coll Cardiol"},{"key":"2770_CR4","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","volume":"18","author":"ML Koschinsky","year":"2024","unstructured":"Koschinsky ML, Bajaj A, Boffa MB et al (2024) A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol 18:e308\u2013e319","journal-title":"J Clin Lipidol"},{"issue":"39","key":"2770_CR5","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG et al (2022) Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 43(39):3925\u20133946","journal-title":"Eur Heart J"},{"key":"2770_CR6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.atherosclerosis.2021.09.027","volume":"349","author":"H Lee","year":"2022","unstructured":"Lee H, Park KS, Jeon YJ et al (2022) Lipoprotein(a) and subclinical coronary atherosclerosis in asymptomatic individuals. Atherosclerosis 349:190\u2013195","journal-title":"Atherosclerosis"},{"key":"2770_CR7","doi-asserted-by":"publisher","first-page":"e024870","DOI":"10.1161\/JAHA.121.024870","volume":"11","author":"OH Obisesan","year":"2022","unstructured":"Obisesan OH, Kou M, Wang FM et al (2022) Lipoprotein(a) and subclinical vascular and valvular calcification on cardiac computed tomography: the atherosclerosis risk in communities study. J Am Heart Assoc 11:e024870","journal-title":"J Am Heart Assoc"},{"key":"2770_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jacc.2021.10.035","volume":"79","author":"LP Dawson","year":"2022","unstructured":"Dawson LP, Lum M, Nerleker N et al (2022) Coronary atherosclerotic plaque regression: JACC state-of-the-art review. J Am Coll Cardiol 79:66\u201382","journal-title":"J Am Coll Cardiol"},{"key":"2770_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jcct.2020.11.002","volume":"15","author":"LJ Shaw","year":"2021","unstructured":"Shaw LJ, Blankstein R, Bax JJ et al (2021) Society of Cardiovascular Computed Tomography \/ North American Society of Cardiovascular Imaging - expert consensus document on coronary CT imaging of atherosclerotic plaque. J Cardiovasc Comput Tomogr 15:93\u2013109","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"2770_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jacc.2021.10.044","volume":"79","author":"Y Kaiser","year":"2022","unstructured":"Kaiser Y, Daghem M, Tzolos E et al (2022) Association of lipoprotein(a) with atherosclerotic plaque progression. J Am Coll Cardiol 79:223\u2013233","journal-title":"J Am Coll Cardiol"},{"key":"2770_CR11","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/eurjpc\/zwae007","volume":"31","author":"DM Leistner","year":"2024","unstructured":"Leistner DM, Laguna-Fernandez A, Haghikia A et al (2024) Impact of elevated lipoprotein(a) on coronary artery disease phenotype and severity. Eur J Prev Cardiol 31:856\u2013865","journal-title":"Eur J Prev Cardiol"},{"key":"2770_CR12","doi-asserted-by":"publisher","first-page":"e016152","DOI":"10.1161\/CIRCIMAGING.123.016152","volume":"17","author":"R Mszar","year":"2024","unstructured":"Mszar R, Cainzos-Achirica M, Valero-Elizondo J et al (2024) Lipoprotein(a) and coronary plaque in asymptomatic individuals: the Miami Heart Study at Baptist Health South Florida. Circ Cardiovasc Imaging 17:e016152","journal-title":"Circ Cardiovasc Imaging"},{"key":"2770_CR13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s00392-018-1369-1","volume":"108","author":"J Eckert","year":"2019","unstructured":"Eckert J, Renczes-Janetzko P, Schmidt M, Magedanz A, Voigtl\u00e4nder T, Schmermund A (2019) Coronary CT angiography (CCTA) using third-generation dual-source CT for ruling out in-stent restenosis. Clin Res Cardiol 108:402\u2013410","journal-title":"Clin Res Cardiol"},{"key":"2770_CR14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3390\/diagnostics14020154","volume":"14","author":"L Weichsel","year":"2024","unstructured":"Weichsel L, Giesen A, Andr\u00e9 F et al (2024) Comparison of two contemporary quantitative atherosclerotic plaque assessment tools for coronary computed tomography angiography: single-center analysis and multi-center patient cohort validation. Diagnostics 14:154","journal-title":"Diagnostics"},{"key":"2770_CR15","unstructured":"Denzinger F, Wels M, Hopfgartner C et al Coronary plaque analysis for CT angiography clinical research. arXiv 2021. Available from:  http:\/\/arxiv.org\/abs\/2101.03799. Accessed 2 Apr 2024"},{"key":"2770_CR16","doi-asserted-by":"publisher","first-page":"e002060","DOI":"10.1136\/openhrt-2022-002060","volume":"9","author":"SE Nissen","year":"2022","unstructured":"Nissen SE, Wolski K, Cho L et al (2022) Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease. Open Heart 9:e002060","journal-title":"Open Heart"},{"key":"2770_CR17","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1093\/eurheartj\/ehae191","volume":"45","author":"BJ Arsenault","year":"2024","unstructured":"Arsenault BJ, Kamstrup PR (2024) Eight reasons why lipoprotein(a) should be measured in everyone at least once in a lifetime. Eur Heart J 45:2692\u20132694","journal-title":"Eur Heart J"},{"key":"2770_CR18","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","volume":"3","author":"S Burgess","year":"2018","unstructured":"Burgess S, Ference BA, Staley JR et al (2018) Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol 3:619\u2013627","journal-title":"JAMA Cardiol"},{"key":"2770_CR19","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa2405182","volume":"391","author":"PM Ridker","year":"2024","unstructured":"Ridker PM, Moorthy MV, Cook NR, Rifai N, Lee IM, Buring JE (2024) Inflammation, cholesterol, lipoprotein(a), and 30-year cardiovascular outcomes in women. N Engl J Med 391:2087\u20132097","journal-title":"N Engl J Med"},{"key":"2770_CR20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/jamacardio.2019.1041","volume":"4","author":"C Lamina","year":"2019","unstructured":"Lamina C, Kronenberg F, Lp(a)-GWAS-Consortium (2019) Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a mendelian randomization analysis. JAMA Cardiol 4:575\u2013579","journal-title":"JAMA Cardiol"},{"key":"2770_CR21","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1016\/j.jacc.2014.01.061","volume":"63","author":"J Tian","year":"2014","unstructured":"Tian J, Ren X, Vergallo R et al (2014) Distinct morphological features of ruptured culprit plaque for acute coronary events compared to those with silent rupture and thin-cap fibroatheroma: a combined optical coherence tomography and intravascular ultrasound study. J Am Coll Cardiol 63:2209\u20132216","journal-title":"J Am Coll Cardiol"},{"key":"2770_CR22","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.jacc.2019.07.062","volume":"74","author":"A Arbab-Zadeh","year":"2019","unstructured":"Arbab-Zadeh A, Fuster V (2019) From detecting the vulnerable plaque to managing the vulnerable patient: JACC state-of-the-art review. J Am Coll Cardiol 74:1582\u20131593","journal-title":"J Am Coll Cardiol"},{"key":"2770_CR23","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1161\/01.CIR.102.17.2063","volume":"102","author":"S Ojio","year":"2000","unstructured":"Ojio S, Takatsu H, Tanaka T et al (2000) Considerable time from the onset of plaque rupture and\/or thrombi until the onset of acute myocardial infarction in humans. Circulation 102:2063\u20132069","journal-title":"Circulation"},{"key":"2770_CR24","doi-asserted-by":"publisher","first-page":"e018023","DOI":"10.1161\/JAHA.120.018023","volume":"9","author":"CP Huded","year":"2020","unstructured":"Huded CP, Shah NP, Puri R et al (2020) Association of serum lipoprotein (a) levels and coronary atheroma volume by intravascular ultrasound. J Am Heart Assoc 9:e018023","journal-title":"J Am Heart Assoc"},{"key":"2770_CR25","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/j.jacc.2024.03.367","volume":"83","author":"MM Yu","year":"2024","unstructured":"Yu MM, Wang ML, Wang JJ et al (2024) Association of lipoprotein(a) levels with myocardial infarction in patients with low-attenuation plaque. J Am Coll Cardiol 83:1743\u20131755","journal-title":"J Am Coll Cardiol"},{"key":"2770_CR26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti J, Wijns W, Saraste A et al (2020) 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 41:407\u2013477","journal-title":"Eur Heart J"},{"key":"2770_CR27","doi-asserted-by":"publisher","first-page":"e017136","DOI":"10.1161\/CIRCIMAGING.124.017136","volume":"17","author":"PF Rodriguez Lozano","year":"2024","unstructured":"Rodriguez Lozano PF, Hosadurg N (2024) Elevated lipoprotein(a) with zero coronary artery calcium: a silent threat or a clinical paradox? Circ Cardiovasc Imaging 17:e017136","journal-title":"Circ Cardiovasc Imaging"},{"key":"2770_CR28","doi-asserted-by":"publisher","first-page":"154706","DOI":"10.1016\/j.metabol.2021.154706","volume":"116","author":"KL Ong","year":"2021","unstructured":"Ong KL, McClelland RL, Allison MA et al (2021) Lipoprotein (a) and coronary artery calcification: prospective study assessing interactions with other risk factors. Metabolism 116:154706","journal-title":"Metabolism"},{"key":"2770_CR29","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jacc.2021.11.058","volume":"79","author":"A Mehta","year":"2022","unstructured":"Mehta A, Vasquez N, Ayers CR et al (2022) Independent association of Lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk. J Am Coll Cardiol 79:757\u2013768","journal-title":"J Am Coll Cardiol"},{"key":"2770_CR30","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1161\/01.CIR.0000159263.50305.BD","volume":"111","author":"R Guerra","year":"2005","unstructured":"Guerra R, Yu Z, Marcovina S, Peshock R, Cohen JC, Hobbs HH (2005) Lipoprotein(a) and apolipoprotein(a) isoforms: no association with coronary artery calcification in the Dallas Heart Study. Circulation 111:1471\u20131479","journal-title":"Circulation"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02770-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-025-02770-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02770-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:30:05Z","timestamp":1765873805000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-025-02770-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2770"],"URL":"https:\/\/doi.org\/10.1007\/s00392-025-02770-w","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"P.B. receives speaker honoraria and consultancy fees from AstraZeneca, Daiichi Sankyo, Novo Nordisk, and Sanofi Aventis, and institutional grants from the German Heart Foundation.\u00a0C.L. receives speaker honoraria from AstraZeneca, Bayer AG, and Boehringer Ingelheim.\u00a0E.L-L. receives lecture honoraria and advisory fees from Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb\/Pfizer, Daiichi Sankyo, Portola, CSL Behring, Norgine, Roche, Leo, AstraZeneca, and Aspen; institutional research support from Bayer AG, Bristol-Myers Squibb\/Pfizer, Daiichi Sankyo, Werfen, and CSL Behring.D.W. receives speaker honoraria from AstraZeneca, Bayer AG, Edwards, Medtronic, Meril,\u00a0Novartis; institutional research support from Abiomed.The other authors declare that they have no conflict of interest regarding this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures and conflict of interest statements"}}]}}